John Cumbers
Founder and CEO at SynBioBeta
Contributor at Forbes
Join @SynBioBeta - May 5-8, 2025 in San Jose: https://t.co/elCGFg5WrJ and read my weekly newsletter: https://t.co/wlPcmG0KfG
Articles
-
2 weeks ago |
synbiobeta.com | John Cumbers
In this episode, John Cumbers speaks with Harshal Chokhawala, co-founder and CEO of ZymoChem, about how the company is reengineering the foundations of materials science using microbial fermentation. Harshal discusses his scientific journey from organic chemistry to building a carbon-conserving biotech platform capable of producing bio-based adipic acid, a key component in nylon 66. Their recent partnership with Lululemon aims to bring sustainable, high-performance textiles to market.
-
Apr 16, 2024 |
synbiobeta.com | John Cumbers
On this SynBioBeta podcast, John Cumbers talks with Edward Shenderovich, the Founder and CEO of Synonym, a company creating bioeconomy infrastructure to help next-generation bioproducts scale and get to market. Edward will speak at this year’s SynBioBeta conference on “Scaling Biological Capacity,” and in today’s episode, John and Edward will discuss how Synonym addresses some of the challenges in biomanufacturing with its technology-driven products and focus.
-
Feb 13, 2024 |
synbiobeta.com | John Cumbers
On this SynBioBeta podcast, John Cumbers talks with Eben Bayer, the CEO of Ecovative, a pioneering company at the forefront of developing sustainable materials using mycelium. John and Eben will discuss Ecovative’s journey toward creating a billion pounds of mycelium, explore some of the cutting-edge agricultural technology used in mushroom growing, and discuss the transformative potential of new mycelium crops in consumer goods.
-
Dec 5, 2023 |
synbiobeta.com | John Cumbers
On this SynBioBeta podcast, John Cumbers talks with Sean McClain, founder, and CEO of Absci, a generative AI drug creation company on a mission to create better drugs for patients faster. Sean and John will continue some of the discussion that we started on the SynBioBeta stage around generative AI and its critical role in drug discovery, some news from AbSci’s recent R&D day, and Sean’s recent visit to Congress to discuss the opportunities and threats from AI and bio.
-
Oct 30, 2023 |
synbiobeta.com | John Cumbers
Today, John Cumbers talks with Ursheet Parikh, a general partner at Mayfield Fund, an early-stage, global venture capital firm with a people-first philosophy and a 50-plus-year history of investing and partnering with founders. John and Ursheet will discuss the state of the synthetic biology market and what startups can do to survive and thrive in this turbulent economy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 13K
- Tweets
- 7K
- DMs Open
- No
Co-author of “Attention Is All You Need,” Jakob Uszkoreit @kyosu helped invent the Transformer—the architecture behind ChatGPT's technology and AlphaFold. At Inceptive, he’s applying deep learning to cellular design, building AI-native RNA therapeutics with $100M in funding. https://t.co/Kf9OlCxT09
If you're new to #SynBioBeta, I invite you to join us at the new Attendee reception on the Monday night of the conference. It's my favorite time of the event where I get to meet all the new members of our community. Please come say hi! May 5, 5PM at San Jose https://t.co/iiBL9qt0SP
The #UnitedStates has always been a global leader in #biotechnology innovation. But unless we act now to scale up our manufacturing capacity, we risk handing the future of this vital industry to #China. Read more on my piece: https://t.co/LehF3BEsqL